Page 2 - Exome Sequencing News Today

HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel

MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, held a Corporate Satellite Meeting and revealed significant local partnerships at the ESHG Conference in Glasgow.

The newest report from Data Bridge Market Research, "Third Generation Sequencing Market" examines growth strategies, drivers, opportunities, key segments,

Bipolar disorder (BD) is a major psychiatric condition that afflicts about 1% of people. Symptoms of BD include sudden onset of depressive mood with loss of interest which alternates with a manic state of hyperactivity.

1. In this cohort study, a combination of exome sequencing, microarray analysis, and phenotypic data improved the detection of rare pediatric diseases. 2. Several factors were identified that impact the probability of successful diagnosis, including the recruitment of a parent-offspring trio. Evidence Rating Level: 2 (Good) Study Rundown: Genomic sequencing has enabled significant progress in

Brisbane, Australia 27th April 2023 - MGI and  South Australian Genomics Centre (SAGC) are proud to announce their joint efforts to advance genomics research in Australia by introducing the country's first commercial ultra-high throughput sequencer DNBSEQ-T7*, through MGI's local distributor Decode Science.

Researchers performed a large-scale sequencing study using data gathered over a decade from a previous study.

This eBook provides an informative guide on how automated solutions can be leveraged to optimize your NGS workflows

A Qualitative Research Study accomplished by Data Bridge Market Researchs database, titled "Whole Genome and Exome Sequencing Market" with 100+ market data

To create the most effective, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, scientists and clinicians need the clearest picture of the genetic changes leading to the cancer's development.